Form 4: Jaguar Health CFO Acquires Convertible Note and Warrants

Carol R. Lizak, CFO of Jaguar Health, acquired a convertible promissory note and warrants to purchase common stock, according to a Form 4 filing.

Summary

• Carol R. Lizak, the Chief Financial Officer of Jaguar Health, Inc., filed a Form 4 indicating changes in beneficial ownership.
• On March 31, 2025, Lizak acquired a 6% convertible promissory note for $30,000, which can be converted into 5,400 shares of common stock at $5.555 per share.
• The note matures three months after issuance.
• Lizak also received a warrant to purchase up to 5,400 shares of common stock at an exercise price of $5.43 per share.
• The warrant is exercisable immediately and expires five years from issuance, upon a fundamental transaction, or a liquidation event.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing simply reports a transaction. The CFO's investment could be seen as a positive signal, but it's not definitively bullish.

Positives

• The CFO's investment could signal confidence in the company's future.

Risks

• The convertible note could lead to dilution of existing shareholders if converted to common stock.

Future Outlook

The document does not contain explicit forward-looking statements, but the acquisition of the convertible note and warrants suggests a potential future increase in the CFO's stake in the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. The acquisition of convertible notes and warrants is a common form of executive compensation and investment.

Comparison to Industry Standards

• Convertible notes and warrants are frequently used in the biotechnology industry to attract investment and compensate executives, especially in smaller companies like Jaguar Health.
• Similar transactions can be seen with companies like Cassava Sciences and Anavex Life Sciences, where executives have received stock options and warrants as part of their compensation packages.
• The terms of the convertible note and warrant (conversion price, exercise price, and expiration date) are within the typical range for such instruments in the biotech sector.

Related Party Transactions

• The issuance of the convertible promissory note and warrant to the CFO, Carol R. Lizak, constitutes a related party transaction.

Stakeholder Impact

• Shareholders may experience dilution if the convertible note is converted and the warrants are exercised.
• The transaction could be viewed positively by stakeholders if it signals confidence from the CFO in the company's prospects.

Key Dates

Keywords

Form 4, Jaguar Health, Convertible Note, Warrant, Beneficial Ownership, CFO, Lizak, JAGX